Related Experiment Video
Updated: Jan 1, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
MicroRNA-31/184 is involved in transforming growth factor-β-induced apoptosis in A549 human alveolar adenocarcinoma
Cong-Jie Wang1, Bing-Bing Li2, Yu-Jun Tan3
1Pulmonary and Critical Care Medicine Ward I, Yantai Yuhuangding Hospital, Yantai, China.
Aims:
TGF-β-induced alveolar epithelial cells apoptosis were involved in idiopathic pulmonary fibrosis (IPF). This study aimed to explore potential targets and mechanisms of IPF.
Main Methods:
mRNA and microRNA arrays were used to analyze differentially expressed genes and miRNAs. Several essential targets of TGF-β-SMADs and TGF-β-PI3K-AKT pathways were detected.
Key Findings:
miR-31 and miR-184 expression levels were positively correlated with smad6 and smad2/akt expression levels in IPF patients. TGF-β could induce miR-31 and suppress miR-184 levels in A549 cells. miR-31 was confirmed to bind to the smad6-3'UTR and functionally suppress its expression. Down-regulated SMAD6 enhanced SMAD2/SMAD4 dimer formation and translocation due to its failure to prevent SMAD2 phosphorylation. In contrast, anti-fibrotic functions of miR-184 were abolished due to TGF-β directly suppressing miR-184 levels in A549 cells. When A549 was stimulated by TGF-β combined with or without miR-31 inhibitor/miR-184 mimic, it was showed that depleted miR-31 and/or increased miR-184 significantly ameliorated TGF-β-induced viability of A549 cells, as well as inhibited the expression of profibrotic factors, MMP7 and RUNX2.
Significance:
Inhibiting miR-31 and/or promoting miR-184 protect against TGF-β-induced fibrogenesis by respectively repressing the TGF-β-SMAD2 and TGF-β-PI3K-AKT signaling pathways, implying that miR-31/184 are potential targets and suggesting a new management strategy for IPF.
Insights
Inhibiting miR-31 and promoting miR-184 can protect against idiopathic pulmonary fibrosis (IPF) by targeting TGF-β signaling pathways. This suggests new therapeutic strategies for IPF management.
Area of Science:
- Molecular Biology
- Cell Biology
- Pulmonary Medicine
Background:
- Idiopathic pulmonary fibrosis (IPF) involves apoptosis in alveolar epithelial cells induced by transforming growth factor-beta (TGF-β).
- Understanding the molecular mechanisms and identifying therapeutic targets are crucial for managing IPF.
Purpose of the Study:
- To explore potential molecular targets and mechanisms underlying idiopathic pulmonary fibrosis (IPF).
- To investigate the roles of specific microRNAs (miRNAs) in TGF-β-induced fibrogenesis.
Main Methods:
- Differential gene and miRNA expression analysis using mRNA and microRNA arrays.
- Detection of key targets within TGF-β-SMADs and TGF-β-PI3K-AKT signaling pathways.
- In vitro experiments using A549 cells to assess miRNA-mRNA interactions and pathway modulation.
Main Results:
- miR-31 and miR-184 expression levels correlated with SMAD6, SMAD2, and AKT in IPF patients.
- TGF-β upregulated miR-31 and downregulated miR-184 in A549 cells.
- miR-31 targeted SMAD6, and miR-184 exhibited anti-fibrotic functions, both modulated by TGF-β. Depleting miR-31 or increasing miR-184 ameliorated TGF-β-induced A549 cell viability and profibrotic factor expression (MMP7, RUNX2).
Conclusions:
- Inhibiting miR-31 and/or promoting miR-184 protect against TGF-β-induced fibrogenesis.
- These miRNAs modulate the TGF-β-SMAD2 and TGF-β-PI3K-AKT signaling pathways.
- miR-31/184 represent potential therapeutic targets for IPF, suggesting novel management strategies.
More Related Videos
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:16TGF - β Signaling Pathway